First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

被引：0
|
作者：
Wenham, R. M. [1 ,2 ]
Sandhu, S. K. [3 ]
Wilding, G. [4 ]
Sun, L. [5 ]
Toniatti, C. [5 ]
Stroh, M. [5 ]
Carpenter, C. [5 ]
de-Bono, J. [3 ]
Baird, R. [3 ]
Schelman, W. R. [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Div Gynecol Oncol, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Div Expt Therapeut, Tampa, FL 33682 USA
[3] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England
[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[5] Merck & Co Inc, Merck Res Labs, Whitehouse Stn, NJ USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72069-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [1] First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers
    Wenham, R.
    Wilding, G.
    Baird, R.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C.
    de-Bono, J.
    Sandhu, S.
    Schelman, W.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S5 - S6
  • [2] First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 with antitumour activity in advanced BRCA-deficient and sporadic cancers
    Garcia, V. M. Moreno
    Wilding, G.
    Sandhu, S. K.
    Schelman, W. R.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Kreischer, N.
    Carpenter, C.
    Molife, L. R.
    Kaye, S.
    de Bono, J. S.
    Wenham, R. M.
    ANNALS OF ONCOLOGY, 2011, 22 : 39 - 39
  • [3] First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
    Schelman, W. R.
    Sandhu, S. K.
    Garcia, V. Moreno
    Wilding, G.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Kreischer, N.
    Carpenter, C. L.
    Molife, L. R.
    Kaye, S. B.
    De Bono, J. S.
    Wenham, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
    Sandhu, S. K.
    Wenham, R. M.
    Wilding, G.
    McFadden, M.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C. L.
    De Bono, J. S.
    Schelman, W. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
    Sandhu, S. K.
    Wilding, G.
    Schelman, W. R.
    Omlin, A.
    Kreischer, N.
    Carpenter, C.
    Iannone, R.
    Kaye, S.
    de-Bono, J. S.
    Wenham, R. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 107 - 108
  • [6] PHASE I STUDY OF A POLY(ADP)-RIBOSE POLYMERASE (PARP) INHIBITOR MK-4827 (MK) WITH ANTITUMOUR ACTIVITY IN SPORADIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Sandhu, S. K.
    Moreno, V.
    Wilding, G.
    Omlin, A.
    Schelman, W. R.
    Miranda, S.
    Riinaes, R.
    Hylands, L.
    Attard, G.
    Cassidy, A.
    Kreischer, N.
    Carpenter, C.
    Demuth, T.
    Wenham, R. M.
    de-Bono, J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 33 - 33
  • [7] In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer
    Al Hilli, Mariam
    Weroha, S. John
    Becker, Marc
    Hou, Xiaonan
    Harrington, Sean
    McKinstrey, Sarah
    Kalli, Kimberly
    Goodman, Karin
    Wilcoxen, Keith
    Swisher, Elizabeth
    Kaufmann, Scott
    Haluska, Paul
    CLINICAL CANCER RESEARCH, 2013, 19
  • [8] Development of MK-4827: A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors
    Jones, Philip
    Altamura, Sergio
    Boueres, Julia
    Ferrigno, Federica
    Fonsi, Massimiliano
    Gavory, Gerald
    Giomini, Claudia
    Koch, Uwe
    Lamartina, Stefania
    Monteagudo, Edith
    Ontoria, Jesus M.
    Roscilli, Giuseppe
    Rowley, Michael
    Scarpelli, Rita
    Schultz-Fademrecht, Carsten
    Toniatti, Carlo
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [9] Development of MK-4827: a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors
    Jones, Philip
    Altamura, Sergio
    Ferrigno, Federica
    Fonsi, Massimiliano
    Gavory, Gerald
    Giomini, Claudia
    Lamartina, Stefania
    Lazzaro, Domenico
    Mesiti, Giuseppe
    Monteagudo, Edith
    Mori, Federica
    Ontoria, Jesus
    Roscilli, Giuseppe
    Scarpelli, Rita
    Rowley, Michael
    Toniatti, Carlo
    CANCER RESEARCH, 2009, 69
  • [10] Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells
    Bridges, Kathleen A.
    Toniatti, Carlo
    Buser, Carolyn A.
    Liu, Huifeng
    Buchholz, Thomas A.
    Meyn, Raymond E.
    ONCOTARGET, 2014, 5 (13) : 5076 - 5086
12345